VivoSim Labs, Inc. (VIVS) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
31/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseVIVS / S&P -25.17% / 15.20% |
LoseVIVS / S&P -21.13% / 15.00% |
WinVIVS / S&P 2135.00% / 50.40% |
| 2026-Q11/3 |
LoseVIVS / S&P -20.99% / -4.33% |
LoseVIVS / S&P -9.03% / 11.30% |
WinVIVS / S&P 197.78% / 27.70% |
| 2025-Q41/3 |
LoseVIVS / S&P -38.01% / 2.65% |
WinVIVS / S&P 16.39% / 9.00% |
LoseVIVS / S&P -107.10% / 13.40% |
| 2025-Q32/3 |
WinVIVS / S&P 98.64% / 8.12% |
WinVIVS / S&P 35.92% / 4.61% |
LoseVIVS / S&P -102.20% / 13.45% |
| 2025-Q21/3 |
LoseVIVS / S&P -34.38% / 10.94% |
WinVIVS / S&P 94.52% / 4.83% |
LoseVIVS / S&P -99.07% / 10.63% |
| 2025-Q11/3 |
LoseVIVS / S&P -59.42% / -4.27% |
WinVIVS / S&P 32.11% / 4.98% |
LoseVIVS / S&P -90.65% / 10.57% |
| 2024-Q41/3 |
LoseVIVS / S&P -9.80% / 2.41% |
LoseVIVS / S&P -49.59% / 5.25% |
WinVIVS / S&P 1035.48% / 6.15% |
| 2024-Q31/3 |
LoseVIVS / S&P -32.89% / 5.89% |
LoseVIVS / S&P -72.01% / 5.89% |
WinVIVS / S&P 963.55% / 6.11% |
| 2024-Q21/3 |
LoseVIVS / S&P -26.21% / 4.28% |
LoseVIVS / S&P -83.60% / 5.38% |
WinVIVS / S&P 945.63% / 5.12% |
| 2024-Q11/3 |
LoseVIVS / S&P -7.21% / 10.56% |
LoseVIVS / S&P -70.54% / 5.71% |
WinVIVS / S&P 877.66% / 5.59% |
| 2023-Q41/3 |
LoseVIVS / S&P -11.20% / 11.69% |
LoseVIVS / S&P -85.83% / 6.81% |
WinVIVS / S&P 61.94% / 7.78% |
| 2023-Q31/3 |
LoseVIVS / S&P -26.04% / -3.27% |
LoseVIVS / S&P -76.66% / 7.52% |
WinVIVS / S&P 56.20% / -5.03% |
| 2023-Q21/3 |
LoseVIVS / S&P -22.83% / 8.74% |
LoseVIVS / S&P -70.33% / 9.50% |
WinVIVS / S&P 48.20% / -8.57% |
| 2023-Q12/3 |
WinVIVS / S&P 55.32% / 7.50% |
LoseVIVS / S&P VIVS unavailable / 10.77% |
WinVIVS / S&P 50.38% / -15.69% |
| 2022-Q40/3 |
LoseVIVS / S&P -31.22% / 7.56% |
LoseVIVS / S&P VIVS unavailable / 11.88% |
LoseVIVS / S&P VIVS unavailable / -17.99% |
| 2022-Q31/3 |
WinVIVS / S&P 15.82% / -4.88% |
LoseVIVS / S&P VIVS unavailable / 13.47% |
LoseVIVS / S&P VIVS unavailable / -1.41% |
| 2022-Q20/3 |
LoseVIVS / S&P -52.93% / -16.10% |
LoseVIVS / S&P VIVS unavailable / 13.71% |
LoseVIVS / S&P VIVS unavailable / 11.04% |
| 2022-Q11/3 |
WinVIVS / S&P 3.58% / -4.60% |
LoseVIVS / S&P VIVS unavailable / 15.97% |
LoseVIVS / S&P VIVS unavailable / 42.23% |
| 2021-Q40/3 |
LoseVIVS / S&P -46.62% / 11.03% |
LoseVIVS / S&P VIVS unavailable / 15.00% |
LoseVIVS / S&P VIVS unavailable / 96.40% |
| 2021-Q30/3 |
LoseVIVS / S&P -27.66% / 0.58% |
LoseVIVS / S&P VIVS unavailable / 10.77% |
LoseVIVS / S&P VIVS unavailable / 69.42% |
| 2021-Q20/3 |
LoseVIVS / S&P -2.49% / 8.55% |
LoseVIVS / S&P VIVS unavailable / 6.58% |
LoseVIVS / S&P VIVS unavailable / 51.81% |
| 2021-Q10/3 |
LoseVIVS / S&P -21.63% / 6.17% |
LoseVIVS / S&P -100.00% / -1.06% |
LoseVIVS / S&P VIVS unavailable / 7.39% |
| 2020-Q41/3 |
WinVIVS / S&P 55.50% / 12.15% |
LoseVIVS / S&P -100.00% / -3.72% |
LoseVIVS / S&P VIVS unavailable / -33.42% |
| 2020-Q30/3 |
LoseVIVS / S&P -28.09% / 8.93% |
LoseVIVS / S&P -91.12% / -2.04% |
LoseVIVS / S&P VIVS unavailable / -27.10% |
| 2020-Q21/3 |
WinVIVS / S&P 34.15% / 20.54% |
LoseVIVS / S&P -50.23% / -0.46% |
LoseVIVS / S&P VIVS unavailable / -27.11% |
| 2020-Q11/3 |
WinVIVS / S&P 13.89% / -19.60% |
LoseVIVS / S&P -28.96% / 3.47% |
LoseVIVS / S&P VIVS unavailable / -14.75% |
| 2019-Q41/3 |
WinVIVS / S&P 38.46% / 9.07% |
LoseVIVS / S&P -18.20% / 5.36% |
LoseVIVS / S&P VIVS unavailable / 2.99% |
| 2019-Q30/3 |
LoseVIVS / S&P -50.00% / 1.70% |
LoseVIVS / S&P -13.70% / 5.02% |
LoseVIVS / S&P VIVS unavailable / 0.21% |
| 2019-Q20/3 |
LoseVIVS / S&P -47.47% / 4.30% |
LoseVIVS / S&P -28.64% / 6.64% |
LoseVIVS / S&P VIVS unavailable / 8.65% |
| 2019-Q10/3 |
LoseVIVS / S&P 3.13% / 13.65% |
LoseVIVS / S&P -32.85% / 8.12% |
LoseVIVS / S&P VIVS unavailable / 14.29% |
| 2018-Q40/3 |
LoseVIVS / S&P -16.52% / -13.52% |
LoseVIVS / S&P -17.64% / 9.05% |
LoseVIVS / S&P VIVS unavailable / 18.23% |
| 2018-Q30/3 |
LoseVIVS / S&P -17.86% / 7.71% |
LoseVIVS / S&P 1.97% / 10.21% |
LoseVIVS / S&P VIVS unavailable / 19.06% |
| 2018-Q22/3 |
WinVIVS / S&P 35.92% / 3.43% |
WinVIVS / S&P 23.51% / 9.03% |
LoseVIVS / S&P VIVS unavailable / 14.46% |
| 2018-Q11/3 |
LoseVIVS / S&P -23.13% / -0.76% |
WinVIVS / S&P 45.34% / 7.68% |
LoseVIVS / S&P VIVS unavailable / 12.46% |
| 2017-Q41/3 |
LoseVIVS / S&P -39.64% / 6.64% |
WinVIVS / S&P 69.88% / 7.03% |
LoseVIVS / S&P VIVS unavailable / 13.82% |
| 2017-Q31/3 |
LoseVIVS / S&P -15.59% / 4.48% |
WinVIVS / S&P 81.06% / 5.68% |
LoseVIVS / S&P VIVS unavailable / 17.57% |
| 2017-Q21/3 |
LoseVIVS / S&P -17.30% / 3.09% |
WinVIVS / S&P 174.04% / 4.83% |
LoseVIVS / S&P VIVS unavailable / 17.74% |
| 2017-Q11/3 |
LoseVIVS / S&P -6.19% / 6.07% |
WinVIVS / S&P 292.93% / 3.67% |
LoseVIVS / S&P VIVS unavailable / 13.32% |
| 2016-Q41/3 |
LoseVIVS / S&P -10.55% / 3.82% |
WinVIVS / S&P 190.86% / 2.09% |
LoseVIVS / S&P VIVS unavailable / 7.05% |
| 2016-Q31/3 |
LoseVIVS / S&P 1.88% / 3.85% |
WinVIVS / S&P 196.76% / 0.20% |
LoseVIVS / S&P VIVS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | VIVS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -88.11% | 20.78% |
| Annualized return | -88.11% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | VIVS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.69% | 83.14% |
| Annualized return | -68.51% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | VIVS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.97% | 319.30% |
| Annualized return | -55.30% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |